

**THE TAMIL NADU Dr. MGR MEDICAL UNIVERSITY, CHENNAI**

**RESULT OF THE Ph.D. SCREENING COMMITTEE - JULY 2013 SESSION**

<b>Sl. No.</b>	<b>NAME OF THE ANDDIATE</b>	<b>SPECIALITY</b>	<b>REMARKS OF THE SCREENING COMMITTEE</b>	<b>RESULT</b>
01	Mrs. S. RENITA RUTH	MICROBIOLOGY	<ul style="list-style-type: none"> <li>✓ To modify the objectives to study newer diagnostic methods among Carbapenem resistant Enterobacteriaceae.</li> <li>✓ To recalculate sample size based on revised objectives.</li> <li>✓ To expand literature review giving more significance to Indian literature.</li> <li>✓ Title also needs to be modified in line with the suggested revisions.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
02	Dr. M. KANNAN	SIDDHA	<ul style="list-style-type: none"> <li>✓ To revise study design and have a randomized controlled clinical trial with a control arm (standard treatment) and an intervention arm (Triphala chooranam). To modify the objectives, sample size and methodology accordingly.</li> <li>✓ To ensure the quality of the drug being used;</li> <li>✓ To revise the "patient information sheet" to provide more details about the study.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>

<b>03</b>	<b>Ms. S. MAHASAMPATH GOWRI</b>	<b>BIOSTATISTICS</b>	<ul style="list-style-type: none"> <li>✓ Novelty and innovativeness of the statistical methods used should be highlighted..</li> <li>✓ Problem should be oriented towards the method rather than the database.</li> <li>✓ Latent class &amp; latent transit models can be explored further;</li> <li>✓ 3<sup>rd</sup> objective should be modified and regression model should be described;</li> <li>✓ What measure will be used to define clusters?</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
<b>04</b>	<b>Mrs. M. GEETHA</b>	<b>NURSING</b>	<ul style="list-style-type: none"> <li>✓</li> <li>✓ Quality of Life - better to limit to one type of cancer preferably with one gender and QOL to compare stage wise and chemotherapy group wise;</li> <li>✓ Multi intervention package details to be included and for acupressure investigator should be a certified trained person.</li> <li>✓ Ethical committee clearance to be obtained.</li> <li>✓ Inclusive age upper limit to be mentioned.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>

05	Mrs. P. NEELA	NURSING	<ul style="list-style-type: none"> <li>✓ Investigator herself is not clear about the study purpose and the Data Collection procedure;</li>   <li>✓ Not able to explain the information on video assisted instructions</li> </ul>	<b>NOT ACCEPTED</b>
06	Mrs. ARZTA SOPHIA	NURSING	<ul style="list-style-type: none"> <li>✓ Investigator needs to undergo training for acupressure and reflexology to be qualified to implement the same.</li>   <li>✓ Gross mistakes in the proposal submitted. Ex. School is mentioned as setting. It is mentioned as 3 sections in the tool whereas it is mentioned only 2 sections in the proposal.</li>   <li>✓ Details of observational checklist is not available.</li>   <li>✓ Application of acupressure &amp; reflexology is not given in detail.</li>   <li>✓ Ethical committee clearance to be obtained.</li>   <li>✓ Data collection procedure is not clear.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>

07	Mrs. C.R. MERLIN SUJA	NURSING	<ul style="list-style-type: none"> <li>✓ To obtain Ethical clearance from the setting Institution;</li> <li>✓ Include the incidence of secondary MI statistics in Tamil Nadu and Hospital of Research;</li> <li>✓ Elaborate the Exercise, Diet, etc and include Social habits - smoking, alcohol etc.,</li> <li>✓ Using check list without observing the performance not appropriate;</li> <li>✓ Follow up in institution and at home not clear.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
08	Mrs. C.S. ANGELIN	NURSING	<ul style="list-style-type: none"> <li>✓ To obtain Ethical clearance from the setting Institution;</li> <li>✓ Decide on control-II term babies;</li> <li>✓ Obtain permission for the tools;</li> <li>✓ Clearly state the Nursing intervention by Researcher &amp; Mother.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>

09	Mrs. C. STARMINE	NURSING	<ul style="list-style-type: none"> <li>✓ Selection of sample at school is not feasible- suitable settings may be chosen;</li> <li>✓ Assessing low self-esteem &amp; depression for this age group is not clear;</li> <li>✓ Ethical committee clearance is mandatory from the setting Institution;</li> <li>✓ Data collection procedure need to be modified.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
10	Mrs. C.D. THILAGAM	NURSING	<ul style="list-style-type: none"> <li>✓ Setting can be changed as college which is ideal and feasible for this study;</li> <li>✓ Written consent from individuals &amp; parents is mandatory;</li> <li>✓ Ethical clearance from the educational institutions' authority is to be obtained;</li> <li>✓ Exclude pharmacotherapy to find out the effectiveness of non-pharmacological intervention;</li> <li>✓ Data collection procedure should be in detail;</li> <li>✓ Tool details should be given in detail.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>

11	Mrs. N. MEENAKUMARI	NURSING	<ul style="list-style-type: none"> <li>✓ Age group should be specified according to the women age group.</li> <li>✓ Administration of almond milk as one of the nursing intervention should be only on experimental group;</li> <li>✓ To obtain TANSAC permission</li> <li>✓ Area &amp; data collection to be specified.</li> <li>✓ Data collection schedule to be produced.</li> <li>✓ Consent of individuals only is not sufficient. It should be according to the marital status.</li> <li>✓ Clarify CD4 would be assessed during the intervention phase in both Experimental &amp; Control group which is not mentioned in the proposal whereas it is emphasized in the presentation.</li> <li>✓ To obtain permission for the tools.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
12	Mrs. M. KAVITHA	NURSING	<ul style="list-style-type: none"> <li>✓ Investigator is not sure about her role in the proposed study. Ex: Mentioned as self interventional preventive strategy but presented as self interventional module i.e. as lecture on selected items.</li> </ul>	<b>NOT ACCEPTED</b>

			<ul style="list-style-type: none"> <li>✓ Not clear about over weight and obesity;</li> <li>✓ Included drug as one of the preventive strategy. Not sure about this;</li> <li>✓ No tool is available with the proposal;</li> <li>✓ Mentioned setting in the proposal is community whereas presented as hospital;</li> <li>✓ Inclusion criteria – not clear – post menopausal with obesity onset before menopause.</li> </ul>	
13	<b>Mrs. C. JASMINE</b>	<b>NURSING</b>	<ul style="list-style-type: none"> <li>✓ Age group not sure for the Investigator regarding children and adolescent</li> <li>✓ Inclusion criteria is not specified in detail;</li> <li>✓ Data collection not clear, mentioned as community in the proposal, these adolescent age group 13-18 will be at school;</li> <li>✓ No tool description is available including the teaching proposal;</li> </ul>	<b>NOT ACCEPTED</b>

			<ul style="list-style-type: none"> <li>✓ No ethical clearance is produced;</li> <li>✓ Data collection schedule not mentioned;</li> <li>✓ Investigator has no experience in working with HIV adolescent.</li> </ul>	
14	Mrs. M. DARJILIN	NURSING	<ul style="list-style-type: none"> <li>✓ Unable to explain the meaning of self enhancement &amp; empowerment;</li> <li>✓ No tools kept in the proposal.</li> <li>✓ No ethical clearance is produced</li> <li>✓ Unable to explain role play and social skill training.</li> <li>✓ Parents involvement not included in the proposal;</li> <li>✓ Data collection procedure not explained;</li> <li>✓ Unable to explain the study.</li> </ul>	<b>NOT ACCEPTED</b>
15	Mrs. S. SHENBAGAVALLI	NURSING	<ul style="list-style-type: none"> <li>✓ Unable to explain the Nursing techniques;</li> </ul>	<b>NOT ACCEPTED</b>

			<ul style="list-style-type: none"> <li>✓ Selection of sample for the proposed study is not appropriate;</li> <li>✓ Unable to explain the data collection procedures;</li> <li>✓ Sampling technique and size estimation is wrongly presented and not clear for the Researcher.</li> </ul>	
16	<b>Mrs. J. BHARATHI</b>	<b>NURSING</b>	<ul style="list-style-type: none"> <li>✓ Not able to explain the specific role of investigator;</li> <li>✓ Proposed study is not upto the level for Ph.D. Programme.</li> </ul>	<b>NOT ACCEPTED</b>
17	<b>Mrs. A. HELEN SONIA</b>	<b>PHARMACY</b>	<ul style="list-style-type: none"> <li>✓ PK work (Bioavailability) may be done</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
18	<b>Mr. K.C. ARUL PRAKASAM</b>	<b>PHARMACY</b>	<ul style="list-style-type: none"> <li>✓ Though the study may be of value, study is not properly planned.</li> <li>✓ Co- guide: A clinical Psychologist and a Diabetologist need be there.</li> </ul>	<b>NOT ACCEPTED</b>
19	<b>Mr. G. SEKAR</b>	<b>PHARMACY</b>	<ul style="list-style-type: none"> <li>✓ The work will have to be logically organized with specific focus on methodology.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>

20	Mr. K. SELVARAJU	PHARMACY	<ul style="list-style-type: none"> <li>✓ Recommended to carryout the pharmacokinetics studies on the selected formulation.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
21	Mr. A. DINESH RAJA	PHARMACY	<ul style="list-style-type: none"> <li>✓ Though the project hypothesis seems acceptable, the proposal needs to be addressed in detail.</li> </ul>	<b>NOT ACCEPTED</b>
22	Mr. A. MADESWARAN	PHARMACY	<ul style="list-style-type: none"> <li>✓ To increase Number of animals for acute toxicity</li> <li>✓ To remove negative controls in animal group</li> <li>✓ No justification for Rota Rod;</li> <li>✓ Models not appropriate for learning impairment or AD. Choose appropriate ones.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
23	Mrs. P. JAGANNATH	PHARMACY	<ul style="list-style-type: none"> <li>✓ Change of title suggested – May be rephrased as “Role of synthesized flavonoids as Cardioprotective prophylactic agents using in silico, invitro and invivo models.</li> <li>✓ Acute toxicity studies – to include more animals</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>

			<ul style="list-style-type: none"> <li>✓ In “invivo studies” – To include atleast one more dose group;</li> <li>✓ Relevant standards to be used in the “invitro studies”.</li> </ul>	
24	Ms. S.E. MAIDA ENGELS	PHARMACY	-----	<b>ACCEPTED</b>
25	Ms. C. SENTIL KUMARI	PHARMACY	<ul style="list-style-type: none"> <li>✓ The plant has been extensively studied. Suggested to change the plant.</li> <li>✓ The work needs to be more exhaustive and should have more depth.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
26	Ms. BABITA K. VAZAYIL	PHARMACY	-----	<b>ACCEPTED</b>
27	Ms. S. GOMATHI	PHARMACY	<ul style="list-style-type: none"> <li>✓ LPS &amp; Stress lacks consisting role in this experiment;</li> <li>✓ One of them may be chosen;</li> <li>✓ Research question and methodology needs greater refining.</li> </ul>	<b>NOT ACCEPTED</b>
28	Mr. S.S. RAJENDRAN	PHARMACY	<ul style="list-style-type: none"> <li>✓ Analog based drug design can be included in the drug design</li> </ul>	<b>ACCEPTED</b>

29	Mr. V.M. ANNAPANDIAN	PHARMACY	<ul style="list-style-type: none"> <li>✓ The plant has already been worked on by Joshi. et. Al</li> <li>✓ Suggested another plant with similar methodology</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
30	Ms. K. SONIA	PHARMACY	<ul style="list-style-type: none"> <li>✓ Title lacks clarity;</li> <li>✓ Work also lacks clarity;</li> <li>✓ Methodology not clear.</li> </ul>	<b>NOT ACCEPTED</b>
31	Mr. VIJAY SHAMRAOJI BORKAR	PHARMACY	<ul style="list-style-type: none"> <li>✓ Isolated Compound to be Evaluated for all the activities.</li> <li>✓ Include Cognostical work, as suggested by Title.</li> </ul>	<b>ACCEPTED WITH RECOMMENDATIONS</b>
32	Mr. S. DIVAKAR	PHARMACY	-----	<b>ACCEPTED</b>
33	Mr. B. EDWIN JOSE	PHARMACY	<ul style="list-style-type: none"> <li>✓ Adequate and relevant literature review suggested;</li> <li>✓ Methodology needs to be clear and detailed;</li> <li>✓ The work needs focus on one selected area.</li> </ul>	<b>NOT ACCEPTED</b>

34	Ms. M. DHANAMANI	PHARMACY	✓ The work can be more specific- Either standardization of plants and formulating a formulation from this Or ✓ Take some formulations which are marketed and then their standardisation may be done.	<b>ACCEPTED WITH RECOMMENDATIONS</b>
35	Ms. B. CHITRA	PHARMACY	-----	<b>ACCEPTED</b>
36	Ms. R.K. SANGEETHA	PHARMACY	-----	<b>ACCEPTED</b>

**ACCEPTED**

**: CANDIDATES ARE INSTRUCTED TO SUBMIT THE JOINING REPORT THROUGH THE GUIDE WITHIN 10 WORKING DAYS FROM THE DATE OF PUBLICATION OF THIS RESULT.**

**ACCEPTED WITH RECOMMENDATIONS**

**: CANDIDATES ARE INSTRUCTED TO SUBMIT THE COMPLIANCE REPORT THROUGH THE GUIDE ON OR BEFORE 07.10.2013.**

**NOT ACCEPTED**

**: CANDIDATES ARE INSTRUCTED TO SUBMIT PROPOSALS (FOUR COPIES) THROUGH THE GUIDE WITHIN THREE MONTHS FROM THE DATE OF PUBLICATION OF THIS RESULT.**

**Sd./-  
VICE CHANCELLOR**

